New Covid-19 Vaccine Valneva

Valneva Receives Conditional Marketing Authorization from UK MHRA for its Inactivated COVID-19 Vaccine


Saint Herblain (France), April 14, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has granted Conditional Marketing Authorization (CMA) for its inactivated whole-virus COVID-19 vaccine candidate, VLA2001, for primary immunization in adults 18 to 50 years of age.

Antigen quantification at Valneva laboratories in Vienna Austria, on Thursday, 06. August 2020. Photo: Akos Stiller


Thomas Lingelbach, Chief Executive Officer of Valneva, commented, “We are extremely pleased with this new authorization and would like to thank the MHRA for their trust and confidence. VLA2001 is the only inactivated whole virus COVID-19 vaccine approved in the UK and this authorization could pave the way for the availability of an alternative vaccine solution for the UK population. We continue to receive messages every day from people who are looking for a more traditional vaccine approach. We believe that this new approval could also lead to additional marketing authorizations in other regions of the world. I would like to personally thank all the people who have been supporting us in this endeavor and our internal teams for all their hard work.”

This new marketing authorization comes in addition to the emergency use authorization which was granted by the Bahraini NHRA in March 2022[1]

If you would like to contact us send an email at : [email protected]